Adult height in children with short stature and idiopathic delayed puberty after different management
|
|
- Alison Ramsey
- 6 years ago
- Views:
Transcription
1 DOI /s y ORIGINAL PAPER in children with short stature and idiopathic delayed puberty after different management Stefano Zucchini & Malgorzata Wasniewska & Mariangela Cisternino & Mariacarolina Salerno & Lorenzo Iughetti & Mohamad Maghnie & Maria Elisabeth Street & Manuela Caruso-Nicoletti & Stefano Cianfarani Received: 9 June 2007 /Accepted: 10 July 2007 # Springer-Verlag 2007 Abstract By retrospectively collecting data from nine Italian centres of pediatric endocrinology, we assessed the different management and final outcome of children with short stature and idiopathic delayed puberty. Data were obtained in 77 patients (54 males, 23 females) diagnosed and followed-up in the various centres during the last 15 years. Inclusion criteria were short stature at initial observation and idiopathic delayed puberty diagnosed during follow-up. At first observation, age was 13.8± 1.0 years and height standard deviation score () was 2.6±0.6 in males. In females age was 13.1±0.9 years and height 2.6±0.4. Local diagnostic and therapeutic protocols included testing for growth-hormone deficiency (six centres) and treatment in case of deficiency or, in the remaining centres, testosterone or no treatment in males, and no treatment in females. At diagnosis, both in males and in females, the auxological features (height, target height and bone age delay) were similar in the patients treated with growth hormone, testosterone or not treated. Overall 32 patients received growth hormone (25 males, 7 females), 33 no treatment (17 males, 16 females) and 12 testosterone. There was no difference in the adult height of males and females in the different treatment groups. In males there were no differences between adult and target S. Zucchini (*) Department of Pediatrics, Azienda Ospedaliero-Universitaria di Bologna S. Orsola-Malpighi, via Massarenti 11, Bologna, Italy zucchini@med.unibo.it M. Wasniewska Department of Pediatrics, University of Messina, Messina, Italy M. Cisternino Department of Pediatric Sciences, Instituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, University of Pavia, Pavia, Italy M. Salerno Department of Pediatrics, Federico II University of Napoli, Napoli, Italy M. Maghnie Department of Pediatrics, Instituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini, University of Genoa, Genova, Italy M. E. Street Department of Pediatrics, University of Parma, Parma, Italy M. Caruso-Nicoletti Department of Pediatics, University of Catania, Catania, Italy S. Cianfarani Department of Public Health and Cell Biology, Tor Vergata University, Roma, Italy L. Iughetti Department of Pediatrics, University of Modena and Reggio Emilia, Modena, Italy
2 height s (growth hormone-treated 0.31±0.79, untreated 0.10±0.82, testosterone-treated 0.05±0.95), between adult and initial height s (growth hormone-treated 1.70± 0.93, untreated 1.55±0.92, testosterone-treated 1.53±1.43) and percentage of subjects with adult height above target height. In females, there were no differences between adult and target height s (growth hormone-treated 0.49±1.13; untreated 0.10±0.97) and between adult and initial height s (growth hormone-treated 1.76±0.92; untreated 1.77± 0.98), whereas a significantly higher percentage of patients remained below target height in the growth hormone-treated group (6/7, 85.7% vs 5/11, 31.3%) (P=0.02). In conclusion, the diagnostic and therapeutic management of the patients with short stature and delayed puberty is different among Italian pediatric endocrinologists. Our data do not support the usefulness of growth-hormone therapy in improving adult height in subjects with short stature and delayed puberty, particularly in the female sex. Keywords Delayed puberty. Short stature.. GH therapy. Testosterone Abbreviations standard deviation score GH growth hormone Introduction The diagnostic and therapeutic approaches of pediatric endocrinologists are often different when dealing with short stature associated with delayed puberty. Historically, therapeutic options include testosterone or oxandrolone in males, estrogens in females or no treatment if the clinician considers that height prediction is satisfactory and psychological repercussions are minor [2, 4, 7 9, 12, 17, 21, 23]. Growth-hormone (GH) treatment is an alternative option if GH secretion is studied and the child is found to be GH deficient [3]. Although most studies using androgens or no treatment report an adult height consistent with that of the parents, statural outcome is sometimes unfavourable, with a significant percentage of subjects ending up below the 3rd centile, as was recently confirmed [13]. We retrospectively collected the adult height data of patients examined for short stature and idiopathic delayed puberty from nine centres of pediatric endocrinology. All subjects had similar clinical characteristics at diagnosis and were differently managed and treated according to local protocols. We were able to compare the outcome of three groups of treatment: GH, testosterone or no treatment in males and no treatment vs GH treatment in females. Aims of our study were to compare the diagnostic management of the different centres and to verify whether the treatments prescribed were associated with a better statural outcome. Patients and methods We retrospectively collected data from 77 patients (54 males, 23 females) who were diagnosed and followed-up in nine Italian pediatric endocrinology university centres during the last 15 years. The patients had to meet both the following inclusion criteria: (1) stature below the 3rd centile and growth velocity <25th centile during the last 12 months (at first observation), and (2) idiopathic delayed puberty. The latter was retrospectively defined as follows: in males testicular volume <3.5 ml at age 13.5 years or <6 ml at age 14.5 years; in females lack of breast development M2 at age 12.5 years or M3 at age 13.5 years (Tanner score). The second parameter (in males testicular volume <6 ml at age 14.5 years and in females lack of breast development M3 at age 13.5 years) was introduced to also include subjects with a borderline value for age at puberty onset, but with a subsequent slow progression of pubertal development leading to a frankly delayed puberty. At first observation, in males, chronological age was 13.8± 1.0 years and height standard deviation score () was 2.6±0.6; in females chronological age was 13.1±0.9 years and height 2.6±0.4. Forty-two subjects and seven subjects respectively reported delayed puberty in one or both parents (as a whole, 63.6% of cases). Subjects with permanent hypogonadism and secondary causes of pubertal delay were not included in the study. Local protocols The various centres adopted different diagnostic and therapeutic protocols. In six centres, the patients were tested for GH deficiency, defined as peak GH <10 μg/l after two different pharmacological stimuli from arginine, l- dopa, clonidine, insulin and glucagon and treated with GH in case of deficiency. In the remaining three centres GH testing was not performed and the patients received either testosterone or no treatment. No centres primed the patients with sex steroids before the pharmacological tests. The choice between testosterone or no treatment in case of normal GH secretion or in the patients not tested was taken individually on the basis of gender (no treatment for female subjects) and on the evaluation of patient psychological disturbances owing to the growth delay (testosterone in case of major psychological suffering). GH dose range was mg kg 1 day 1 with seven injections per week. Therapy duration range was months. Depot testosterone (testosterone enanthate i.m.) dose ranged from 25 to 50 mg/month for a duration range of 3 12 months. Estrogen therapy was not used by any centre.
3 The parameters considered for statistical analysis were height at diagnosis expressed as, bone age delay, target height, increase in adult height defined both as the increase compared with height at diagnosis and the difference from target height. Height was calculated with different parameters for children of northern-central Italy and children of southern Italy as appropriate [5, 6]. was defined when growth velocity fell below 1 cm in the last year of observation. Differences among groups were calculated using one-way ANOVA for multiple comparisons (Bonferroni test) in males and with Student t-test in females. The percentage of subjects with adult height above target height was analyzed using the chisquare test. Results In males, mean chronological age at testicular volume 3.5 ml was 14.5±0.9 years. In females mean chronological age at breast development 2 was 14.1±0.7 years and mean age at menarche 15.9±1.5 years. In total, 42 subjects were tested for GH deficiency; 32 (25 males and 7 females) showed GH deficiency and were hence treated with GH. In the remaining 10 cases with normal GH secretion, the subjects received either no treatment (2 males, 3 females) or depot testosterone (5 males). As for the 35 subjects not tested for GH deficiency, 28 patients received no treatment (15 males, 13 females) and 7 testosterone (all males). The auxological features of the patients at diagnosis did not differ in the different groups of treatment and are reported in Table 1. At the end of follow-up, no significant differences among groups were detected (Table 2). In males, the percentage of subjects with adult height above target height was not different in the three groups, whereas in females a significantly higher percentage of subjects remained below target height in the GH-treated group (6/7, 85.7% vs 5/11, 31.3%) (P=0.02). Discussion The present study shows the different management and final outcome of a patient series of Italian subjects affected by short stature and idiopathic delayed puberty. Our definition of delayed puberty could not be based on national data about the normal timing for puberty onset as such data are not available. However, the mean values we obtained for the appearance of Tanner G2 in males and for age at menarche in girls are in agreement with values for delayed puberty found in most industrialised countries [16]. Also the presence of a positive family history in about twothirds of our cases was helpful in confirming our diagnosis. The first result is that the management of children with short stature and delayed puberty is not uniform in Italian centres of pediatric endocrinology, both in terms of diagnostic approach and in type of therapy. Some centres in fact did not consider the simultaneous presence of pubertal delay in addition to short stature and simply performed GH testing. As for the possible therapy prescription in males, some centres tended to propose GH therapy in cases of deficiency, others tended to use testosterone in cases of normal GH secretion and yet others were probably more inclined, in male patients, not to perform any GH testing and simply to reassure the boy and the family that no treatment was necessary for what was considered a self-limiting problem. The therapeutic attitude in the different centres was more similar towards female patients, i.e., no centres used estrogens to correct the statural defect associated with pubertal delay. This was probably due both to a lesser demand from the girls to accelerate the pubertal progression and to uncertainties of the physicians as to the possible negative effects of estrogens on bone age. Furthermore, probably due to the lower prevalence of delayed puberty in females, little has been published about estrogen therapy in females, and also a published consensus guideline [9] was unable to define fixed criteria for treating pubertal delay in females. Estrogens in fact are mainly used to induce and Table 1 Clinical characteristics at entry of the patients, subdivided into the three groups of treatment Males Females (n=54) Height at diagnosis Target height Bone age delay at diagnosis (years) (n=23) Height at diagnosis Target height Bone age delay at diagnosis (years) GH treated (n=25) Untreated (n=17) Testosterone treated (n=12) 2.62± ± ±0.93 GH treated (n=7) 2.57± ± ±0.92 Untreated (n=16) 2.83± ± ± ± ± ± ± ± ±0.52
4 Table 2 Clinical characteristics of patients at the end of growth subdivided into the three groups of treatment Males Females (n=54) Adult height () target height initial height (n=23) Adult height () target height initial height GH treated (n=25) Untreated (n=17) Testosterone treated (n=12) 0.92± ± ±0.93 GH treated (n=7) 1.02± ± ±0.82 Untreated (n=16) 1.39± ± ± ± ± ± ± ± ±0.98 sustain puberty in subjects with permanent hypogonadism [20]. The centres participating in the study did not prime the patients with sex hormones before testing for GH. A probable interpretation of this homogeneous behaviour is that the centres more in favour of GH therapy did not agree with this diagnostic procedure, whereas those against the diagnosis of GH deficiency in this condition simply prescribed testosterone or no treatment. On the other hand, the subject continues to be debated [22], as does the usefulness of pharmacological tests in predicting response to treatment [10]. Concerning the adult height collected in nine Italian centres of pediatric endocrinology, we are obviously aware that our retrospective study was not randomly designed to identify the best treatment for improving adult height among GH, testosterone in males or no treatment in subjects with short stature and delayed puberty. However, to our knowledge, no such studies have been published so far. Despite the different diagnostic approaches of the various centres, we are convinced that the subjects examined were clinically quite similar, whether tested or not for GH deficiency and irrespective of the GH response to pharmacological tests. Since priming with sex steroids was not used in our patients, we cannot exclude that a significant percentage of our patients were falsely diagnosed as GH deficient [14] and maybe showed a blunted response to GH. However, in our opinion, our group of subjects showed similar clinical characteristics and if GH treatment had obtained a consistent height improvement, we would have been able to recognise it, despite the relatively small number of subjects. Our data, in fact, showed a similar statural outcome in the three treatment groups. First of all, in the male group, we confirm [2, 4, 9, 12, 17, 23] that testosterone therapy, useful for mitigating the psychological distress of the adolescent with delayed puberty, seems to lead to a similar adult height as the other groups. Second, GH treatment at the dose given, the most expensive and disturbing treatment in terms of daily injections, seemed to produce no effects or even negative effects in our relatively small group of female patients. In fact, we found a higher percentage of female subjects with adult height below target height in the GH-treated group. On the other hand, the efficacy of GH therapy in the pubertal period except in cases of severe GH deficiency has not been demonstrated in either sex [18], and our data confirm the previous studies by Bierich et al. [3] and Adan et al. [1]. In comparison to what has been reported in the literature, a diagnosis of GH deficiency and subsequent replacement therapy were quite common (Table 1, 41% of cases) in the present case series, reflecting a probably unjustified expectation of the efficacy of GH treatment in this condition. Certainly the GH dose used in our patients mainly diagnosed in the 1990s was lower than that used successfully by Mauras et. al [15] in the pubertal period. Certainly new therapeutic options are needed to improve adult height in some of these patients, in particular for those at risk of becoming excessively short. Preliminary data showed that aromatase inhibitor letrozole has proved to be effective on near adult height in boys with constitutional delay of growth and puberty [11]. However, current limitations on height prediction in this kind of subject should always be considered [19]. Acknowledgements We are grateful to Professor Filippo De Luca for the critical revision of the manuscript. References 1. Adan L, Souberbielle JC, Brauner R (1994) Management of the short stature due to pubertal delay in boys. J Clin Endocrinol Metab 78: Arrigo T, Cisternino M, De Luca F, Saggese G, Messina MF, Pasquino AM, De Sanctis V (1996) Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. J Pediatr Endocrinol Metab 9: Bierich JR, Nolte K, Drews K, Brugmann G (1992) Constitutional delay of growth and adolescence. Results of short-term and longterm treatment with GH. Acta Endocrinol 127:
5 4. Brook CG (1999) Treatment of late puberty. Horm Res 51(Suppl 3): Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, Chiarelli F, Pasquino AM, Tonini G, Vanelli M (2002) Italian cross-sectional growth charts for height, weight and BMI (6 20 y). Eur J Clin Nutr 56: Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gargantini L, Greggio N, Tonini G, Cicognani A (2006) Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Investig 29: Crowne EC, Shalet SM, Wallace WH, Eminson DM, Price DA (1990) Final height in boys with untreated constitutional delay in growth and puberty. Arch Dis Child 65: Crowne EC, Shalet SM, Wallace WH, Eminson DM, Price DA (1991) Final height in girls with untreated constitutional delay in growth and puberty. Eur J Pediatr 150: De Luca F, Argente J, Cavallo L, Crowne E, Delemarre-Van de Waal HA, De Sanctis C, Di Maio S, Norjavaara E, Oostdijk W, Severi F, Tonini G, Trifiro G, Voorhoeve PG, Wu F (2001) International Workshop on Management of Puberty for Optimum Auxological Results. Management of puberty in constitutional delay of growth and puberty. J Pediatr Endocrinol Metab 14(Suppl 2): Gandrud LM, Wilson DM (2004) Is growth hormone stimulation testing in children still appropriate? Growth Horm IGF Res 14: Hero M, Wickman S, Dunkel L (2006) Treatment with the aromatase inhibitor letrozole during adolescence increases nearfinal height in boys with constitutional delay of puberty. Clin Endocrinol 64: Kelly BP, Paterson WF, Donaldson MD (2003) Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone 125 mg per month for 3 months. Clin Endocrinol 58: Krajewska-Siuda E, Malecka-Tendera E, Krajewski-Siuda K (2006) Are short boys with constitutional delay of growth and puberty candidates for rgh therapy according to FDA recommendations? Horm Res 65: Martinez AS, Domene HM, Ropelato MG, Jasper HG, Pennisi PA, Escobar ME, Heinrich JJ (2000) Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab 85: Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 85: Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP (2003) The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev 24: Pozo J, Argente J (2003) Ascertainment and treatment of delayed puberty. Horm Res 60(Suppl 3): Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, Cowell CT, Price DA, Reiter EO (2003) The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 88: Rapaport R (2006) predictions for constitutional growth delay, growth hormone treatment for idiopathic short stature and the FDA: are they related? Horm Res 65: Rubin K (2005) Hypogonadism in adolescent females: new insights and rationale supporting the use of physiologic regimens to induce puberty. Pediatr Endocrinol Rev 2: Volta C, Ghizzoni L, Buono T, Ferrari F, Virdis R, Bernasconi S (1988) Final height in a group of untreated children with constitutional growth delay. Helv Paediatr Acta 43: Wyatt DT, Mark D, Slyper A (1995) Survey of growth hormone treatment practices by 251 pediatric endocrinologists. J Clin Endocrinol Metab 80: Zachmann M, Studer S, Prader A (1987) Short-term testosterone treatment at bone age of 12 to 13 years does not reduce adult height in boys with constitutional delay of growth and adolescence. Helv Paediatr Acta 42:21 28
Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age of 2 years
European Journal of Endocrinology (2000) 142 460 465 ISSN 0804-4643 CLINICAL STUDY Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age
More informationThe science behind igro
The science behind igro igro is an interactive tool that can help physicians evaluate growth outcomes in patients receiving growth hormone (GH) treatment. These pages provide an overview of the concepts
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationDose Effects of Growth Hormone during Puberty
Puberty Horm Res 2003;60(suppl 1):52 57 DOI: 10.1159/000071226 Dose Effects of Growth Hormone during Puberty Paul Saenger Department of Pediatrics, Division of Pediatric Endocrinology, Childrens Hospital
More informationReview Article. Insulin like Growth Factors and Growth Hormone Deficiency
Review Article Insulin like Growth Factors and Growth Hormone Deficiency Sangeeta Yadav Sriram Krishnamurthy Insulin-like growth factors (IGFs) are polypeptides that act as endocrine mediators of growth
More informationZohreh Karamizadeh, MD; Anis Amirhakimi*, MD; Gholamhossein Amirhakimi, MD
Original Article Iran J Pediatr Jun 2014; Vol 24 (No 3), Pp: 293-299 Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly
More informationEffect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
Biomedical Research 2017; 28 (15): 6813-6817 ISSN 0970-938X www.biomedres.info Effect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More informationClinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE
Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationRunning title: Growth hormone coverage for idiopathic short stature
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2016-8 Program Prior Authorization/Medical Necessity Medication Human Growth Hormone: Somatropin (Genotropin *, Humatrope *, Norditropin
More information4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU!
Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management Kent Reifschneider, MD CHKD / EVMS Norfolk, VA Conflict of Interest Speaker bureau and advisor for Pfizer Board member of The
More informationSomatostatin Analog and Estrogen Treatment in a Tall Girl
Clin Pediatr Endocrinol 1995; 4 (2): 163-167 Copyright (C) 1995 by The Japanese Society for Pediatric Endocrinology Somatostatin Analog and Estrogen Treatment in a Tall Girl Toshiaki Tanaka, Mari Satoh,
More informationIT IS WIDELY recognized that the diagnosis of GH deficiency
0021-972X/97/$03.00/0 Vol. 82, No. 2 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Biochemical s in the Diagnosis of Childhood Growth Hormone
More informationUNIVERSITY OF GENOVA CURRICULUM VITAE
UNIVERSITY OF GENOVA CURRICULUM VITAE Genova, 07.06.2013 NAME: MOHAMAD MAGHNIE CURRENT TITLE & DEPARTMENT: Associate Professor of Pediatrics Department of Pediatrics, School of Medicine Director, Pediatric
More informationOriginal article Central Eur J Paed 2018;14(1):68-72 DOI /p
Original article Central Eur J Paed 2018;14(1):68-72 DOI 10.5457/p2005-114.201 Growth hormone treatment in children born small for gestational age: One center s experience Sandra Stanković 1, Saša Živić
More informationCONSENSUS STATEMENT. J Endocrinol Invest DOI /s
DOI 10.1007/s40618-014-0201-7 CONSENSUS STATEMENT Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric
More informationClinical Standards for GH Treatment in Childhood & Adolescence.
Clinical Standards for GH Treatment in Childhood & Adolescence. The Clinical Standards for GH treatment have been produced by the Clinical Committee of the BSPED. They are evidence based where possible
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2018 P 1039-8 Program UnitedHealthcare Pharmacy Clinical Pharmacy Programs Prior Authorization/Notification Human Growth Hormone, Growth Stimulating Products Medication Human Growth Hormone:
More informationR ecombinant growth hormone (GH) treatment is recommended
126 ORIGINAL ARTICLE The investigation of short stature: a survey of practice in Wales and suggested practical guidelines C Evans, J W Gregory, on behalf of the All Wales Clinical Biochemistry Audit Group...
More informationAdherence to Growth Hormone Therapy: A Practical Approach
HORMONE RESEARCH IN PÆDIATRIC S Original Paper Received: October 14, 2013 Accepted: December 12, 2013 Published online: Adherence to Growth Hormone Therapy: A Practical Approach M. Bozzola a S. Pagani
More informationThree-Year Growth Response to Growth Hormone Treatment in Very Young Children Born Small for Gestational Age Data from KIGS
ORIGINAL ARTICLE Endocrine Care Three-Year Growth Response to Growth Hormone Treatment in Very Young Children Born Small for Gestational Age Data from KIGS Margaret C. S. Boguszewski, Anders Lindberg,
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationOriginal. Tsuyoshi Isojima 1), 2), 3), Tomonobu Hasegawa 1), 4), Susumu Yokoya 1), 5) 1), 6) and Toshiaki Tanaka
2017, 64 (9), 851-858 Original The response to growth hormone treatment in prepubertal children with growth hormone deficiency in Japan: Comparing three consecutive years of treatment data of The Foundation
More informationHyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea
Clin Pediatr Endocrinol 1996; 5(2), 61-66 Copyright (C) 1996 by The Japanese Society for Pediatric Endocrinology Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea Toshihisa Okada, Soroku
More informationHHS Public Access Author manuscript Endocr Pract. Author manuscript; available in PMC 2017 March 09.
BIRD S-EYE VIEW OF GnRH ANALOG USE IN A PEDIATRIC ENDOCRINOLOGY REFERRAL CENTER Sara E. Watson, MD, MS 1, Ariana Greene, BS 1, Katherine Lewis, MD, MS 2, and Erica A. Eugster, MD 1 1 Section of Endocrinology
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationand LHRH Analog Treatment in
Endocrine Journal 1996, 43 (Suppl), S13-S17 Combined GH Short Children and LHRH Analog Treatment in TosHIAKI TANAKA***, MARL SATOH**, AND ITSURo HIBI* *Division of Endocrinology & Metabolism, National
More informationGrowth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
Sotos and Tokar International Journal of Pediatric Endocrinology 2014, 2014:15 RESEARCH Open Access Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison
More informationThe New England Journal of Medicine EFFECT OF GROWTH HORMONE TREATMENT ON ADULT HEIGHT OF CHILDREN WITH IDIOPATHIC SHORT STATURE.
EFFECT OF GROWTH HORMONE TREATMENT ON ADULT HEIGHT OF CHILDREN WITH IDIOPATHIC SHORT STATURE RAYMOND L. HINTZ, M.D., KENNETH M. ATTIE, M.D., JOYCE BAPTISTA, PH.D., AND ALEX ROCHE, PH.D., FOR THE GENENTECH
More informationFailure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency
Arch Dis Child 999;8:3 7 3 Failure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency H Mitchell, M T Dattani, V Nanduri, P C Hindmarsh, M A Preece, C G D Brook London Centre for Paediatric Endocrinology,
More informationX/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Prediction of Long-Term Response to Recombinant Human
More informationA lthough it is assumed that growth hormone (GH) secretion
215 ORIGINAL ARTICLE High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature G A Kamp, J J J Waelkens, S
More informationWhy is my body not changing? Conflicts of interest. Overview 11/9/2015. None
Why is my body not changing? Murthy Korada Pediatrician, Pediatric Endocrinologist Ridge Meadows Hospital Surrey Memorial Hospital None Conflicts of interest Overview Overview of normal pubertal timing
More informationImprovement of treatment adherence with growth hormone by easypod device: experience of an Italian centre
Maggio et al. Italian Journal of Pediatrics (2018) 44:113 https://doi.org/10.1186/s13052-018-0548-z RESEARCH Improvement of treatment adherence with growth hormone by easypod device: experience of an Italian
More informationClinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION
Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION Date of First Issue 01/04/2015 Approved 28/01/2016 Current Issue Date 28/01/2016 Review
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationJudith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction
Hindawi Publishing Corporation International Journal of Pediatric Endocrinology Volume 2010, Article ID 494656, 7 pages doi:10.1155/2010/494656 Research Article Factors Influencing the One- and Two-Year
More informationV. CALCATERRA*, P. SAMPAOLO, C. KLERSY, D. LARIZZA*, A. ALFEI, V. BRIZZI*, F. BENEVENTI and M. CISTERNINO*
Ultrasound Obstet Gynecol 2009; 33: 85 91 Published online 11 December 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.6271 Utility of breast ultrasonography in the diagnostic
More informationFinal Height in Patients with Turner Syndrome after
Clin Pediatr Endocrinol 1997; 6(Suppl 10), 51-57 Copyright (C) 1997 by The Japanese Society for Pediatric Endocrinology Final Height in Patients with Turner Syndrome after Treatment with GH Kazue Takano,
More informationTreatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
Original article https://doi.org/10.6065/apem.2017.22.4.259 Ann Pediatr ocrinol Metab 2017;22:259-265 Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious
More informationEffect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome
ORIGINAL ARTICLE Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome Ping-Yi Hsu, Yi-Ching Tung, Wen-Yu Tsai,* Jing-Sheng Lee, Pei-Hung Hsiao Background/Purpose: Short stature
More informationLee et al. International Journal of Pediatric Endocrinology 2012, 2012:22
Lee et al. International Journal of Pediatric Endocrinology 2012, 2012:22 RESEARCH Open Access Comparison of response to 2-years growth hormone treatment in children with isolated growth hormone deficiency,
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationSubmitted: Accepted: Published online:
Neuroendocrinology Letters Volume 34 No. 3 2013 O R I G I N A L A R T I C L E Significant increase of IGF-I concentration and of IGF-I/IGFBP-3 molar ratio in generation test predicts the good response
More informationEffect of growth hormone therapy on Taiwanese children with growth hormone deficiency
Journal of the Formosan Medical Association (2012) 111, 355e363 Available online at www.sciencedirect.com journal homepage: www.jfma-online.com ORIGINAL ARTICLE Effect of growth hormone therapy on Taiwanese
More informationShort boys treated with growth hormone show normal progression of testicular size and achieve normal serum testosterone concentrations
European Journal of Endocrinology (2002) 146 681 685 ISSN 0804-4643 CLINICAL STUDY Short boys treated with growth hormone show normal progression of testicular size and achieve normal serum testosterone
More informationGrowth disorders in adolescents
FOCUS Growth disorders in adolescents Tashunka Taylor-Miller, Peter J Simm Background Growth is one of the fundamental processes of adolescent development. Careful history and examination, and relevant
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationPuberty and Pubertal Disorders Part 3: Delayed Puberty
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 3: Delayed Puberty These podcasts are designed to give medical students an overview
More informationCase Report Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase Inhibitor
Case Reports in Pediatrics Volume 2015, Article ID 738571, 4 pages http://dx.doi.org/10.1155/2015/738571 Case Report Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase
More informationTHE BIOCHEMICAL DIAGNOSIS of GH deficiency
0021-972X/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Estrogen Priming Effect on Growth Hormone (GH) Provocative
More informationOZGROW Report 2009/2010
OZGROW Report 2009/2010 GH therapy in Australia As of May 2010 there are 1636 children receiving GH treatment in Australia under the PBS. The Department of Health and Ageing s (DoHA) indication for GH
More informationFinal height in isolated GH deficiency type 1A: effects of 5-year treatment with IGF-I
European Journal of Endocrinology (2001) 144 379±383 ISSN 0804-4643 CLINICAL STUDY Final height in isolated GH deficiency type 1A: effects of 5-year treatment with IGF-I M F Messina, F De Luca, M Wasniewska,
More informationPubertal evaluation of adolescent boys with -thalassemia major and delayed puberty
Pubertal evaluation of adolescent boys with -thalassemia major and delayed puberty Hala Saleh Al-Rimawi, M.D., F.R.C.P., a Mohammad Fayez Jallad, M.D., M.R.C.O.G., b Zouhair Odeh Amarin, M.D., F.R.C.O.G.,
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Zomacton (somatropin) Must
More informationCircle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]
05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationPAOLA DURAN, MD PEDIATRIC ENDOCRINOLOGIST CENPA, FCI COLOMBIA
PAOLA DURAN, MD PEDIATRIC ENDOCRINOLOGIST CENPA, FCI COLOMBIA GH has important effects on the intermediary metabolism of Carbohydrates Lipids Proteins Acute effects similar to insulin: hypoglycemia enhances
More informationEndocrine: Precocious Puberty Health care guidelines for Spina Bifida
Endocrine: Precocious Puberty Health care guidelines for Spina Bifida Precocious Puberty Primary outcome: Timely assessment, identification, appropriate referral, and management of precocious puberty.
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationAnnalisa Deodati, research fellow, Stefano Cianfarani, associate professor
Molecular Endocrinology Unit- DPUO, Bambino Gesù Children s Hospital Rina Balducci Center of Pediatric Endocrinology, Tor Vergata University, Rome, Italy Correspondence to: S Cianfarani, Department of
More informationGrowth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮
Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000
More informationGrowth Hormone: Review of the Evidence
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Growth Hormone: Review of the Evidence
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
Page 1 Somatropin INITIAL APPLICATION - growth hmone deficiency in children Growth hmone deficiency causing symptomatic hypoglycaemia, with other significant growth hmone deficient sequelae (e.g. cardiomyopathy,
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Mecasermin (Increlex) Reference Number: CP.PHAR.150 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)
More informationPUBLICATIONS Abstracts and publications on the psychological data available.
Page 1 of 9 Synopsis TITLE OF TRIAL : The Effects of Biosynthetic Human Growth Hormone Treatment in the Management of Children with Familial Short Stature. Protocol B: A Comparative Evaluation of Growth
More informationLeuteinizing hormone responses to leuprolide acetate discriminate between hypogonadotropic hypogonadism and constitutional delay of puberty
FERTILITY AND STERILITY VOL. 77, NO. 3, MARCH 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Leuteinizing hormone
More informationGrowth Hormone & IGF Research
Growth Hormone & IGF Research 22 (2012) 134 138 Contents lists available at SciVerse ScienceDirect Growth Hormone & IGF Research journal homepage: www.elsevier.com/locate/ghir Serum insulin-like growth
More informationProspective evaluation of the natural course of idiopathic subclinical hypothyroidism in childhood and adolescence
European Journal of Endocrinology (2009) 160 417 421 ISSN 0804-4643 CLINICAL STUDY Prospective evaluation of the natural course of idiopathic subclinical hypothyroidism in childhood and adolescence Malgorzata
More informationGrowth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain
Lundberg et al. BMC Endocrine Disorders (2015) 15:84 DOI 10.1186/s12902-015-0080-8 RESEARCH ARTICLE Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain Open Access Elena Lundberg
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Mecasermin Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 5/15/2017 Next
More informationKJLM. Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty INTRODUCTION. Original Article Clinical Chemistry
Korean J Lab Med 2011;31:244-249 Original Article Clinical Chemistry Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty Han Kyul Kim, M.D. 1, Seung Jung Kee, M.D. 2, Ji Yeon Seo, M.D.
More informationPrior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products
Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign
More informationPubertal Development in Japanese Boys
Clin Pediatr Endocrinol 1993; (SuPP13): 7-14 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Pubertal Development in Japanese Boys Kenji Fujieda, M.D., Ph. D. Department of Pediatrics,
More informationGrowth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5
Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationHow to approach a child with growth concern
How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic Nothing to disclose Disclosure Objectives To understand
More informationFinal Height in Short Children Born Small for Gestational Age Treated with Growth Hormone
0031-3998/05/5702-0216 PEDIATRIC RESEARCH Vol. 57, No. 2, 2005 Copyright 2004 International Pediatric Research Foundation, Inc. Printed in U.S.A. Final Height in Short Children Born Small for Gestational
More informationDilemmas in Choosing and Using Growth Charts
Dilemmas in Choosing and Using Growth Charts Michael Hermanussen 1, MD, Kaspar Staub 2, PhD, Christian Aβmann 3, PhD, Stef van Buuren 4, 5, PhD 1 Aschauhof, 24340 Altenhof, Germany; 2 Centre for Evolutionary
More informationand Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects
Serum Follicular - Stimulating Hormone and Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects ROBERT PENNY, THOMAS P. FOLEY, JR., and ROBERT
More informationIncreased prevalence of growth hormone deficiency in patients with vernal keratoconjuntivitis; An interesting new association
HORMONES 2014, 13(3):382-388 Research paper Increased prevalence of growth hormone deficiency in patients with vernal keratoconjuntivitis; An interesting new association Stefano Stagi, 1 Neri Pucci, 1
More informationTitle: Growth Hormone Treatment for Adult Growth Hormone Deficiency
Title: Growth Hormone Treatment for Adult Growth Hormone Deficiency Date: 05 October, 2007 Context and policy issues: Growth hormone (GH) is produced by the pituitary gland and plays a role in increasing
More informationAppendix 1: Syndrome-Specific Growth Charts
Appendix 1: Syndrome-Specific Growth Charts Figure A1.1 Height centiles for girls with untreated Turner syndrome aged 1 20 years. The gray-shaded area represents the 3rd to 97th centiles for normal girls.
More informationGrowth and Development in Turner Syndrome
Growth and Development in Turner Syndrome Edna Roche Consultant Paediatric Endocrinologist, National Children s Hospital, AMNCH and the University of Dublin Trinity College Growth in Turner Syndrome Short
More informationNo cases of precocious puberty were reported during clinical trials of risperidone in, cases of precocious puberty have been
levels than adults. The growth hormone elevations reported for the 12 patients with growth hormone excess were modest and well below levels reported in children with gigantism. 7,8 None of the patients
More informationGrowth and metabolic consequences of growth hormone treatment in prepubertal short normal children
Archives of Disease in Childhood 1994; 71: 21-26 Southampton University Hospitals Trust, Tremona Road, Southampton S9 4XY, Department of Child Health E S McCaughey J Mulligan L D Voss Department of Paediatrics
More informationThe development of a manageable medical
Developing a Rational Approach for the Use of Growth Hormone in npediatric Patients David Cook, MD; and Gary Owens, MD The development of a manageable medical policy that ensures appropriate use of recombinant
More informationEfficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study
J Endocrinol Invest DOI 10.1007/s40618-015-0418-0 ORIGINAL ARTICLE Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study M. Cappa1
More informationPROSPECTIVE EVALUATION OF THE NATURAL COURSE OF IDIOPATHIC SUBCLINICAL HYPOTHYROIDISM IN
Page 1 of 22 Accepted Preprint first posted on 12 December 2008 as Manuscript EJE-08-0625 PROSPECTIVE EVALUATION OF THE NATURAL COURSE OF IDIOPATHIC SUBCLINICAL HYPOTHYROIDISM IN CHILDHOOD AND ADOLESCENCE
More informationGuideline for using growth hormone in paediatric patients in South Africa: Treatment of growth hormone deficiency and other growth disorders
Guideline Guideline for using growth hormone in paediatric patients in South Africa: Treatment of growth hormone deficiency and other growth disorders David Segal, on behalf of the Paediatric and Adolescent
More information